Research firm IMARC Group expects this market to grow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report & Forecast: 2012-2016”.

1. New Report Analyzes the Potential of Therapeutic Monoclonal
Antibodies in India
Research firm IMARC Group expects this market to grow at a CAGR of around 26% during
2013-2016, according to its latest report entitled “Indian Monoclonal Antibodies Market Report &
Forecast: 2012-2016”.
A huge patient pool, increasing prevalence of health insurance, strong biosimilar manufacturing
capabilities and a largely unpenetrated market are expected to be the catalysts in driving the
market for monoclonal antibodies in India. Research firm IMARC Group expects this market to
grow at a CAGR of around 26% during 2013-2016, according to its latest report entitled “Indian
Monoclonal Antibodies Market Report & Forecast: 2012-2016”.
According to an analyst at IMARC Group, “India’s poor historical track record in Intellectual
property protection has resulted in many Indian companies acquiring strong reverse engineering
skills. The Indian generic industry provides generic drugs not only to India but to the entire
world. India currently has more FDA approved manufacturing facilities than any other country
outside the US. Globally there are only 2 approved biosimilar monoclonal antibodies with
Reditux (Rituximab) (developed and manufactured by Dr. Ready’s, an Indian generic
manufacturer) being one of them. As a result, India and its biosimilar manufacturers can be
regarded as the front runners in the global biosimilar antibody market race”.
Key Aspects Analyzed in this Report:
Understanding the strengths, weaknesses, opportunities and challenges in the Indian
monoclonal antibodies market
Understanding the technological considerations and regulatory factors in the Indian
monoclonal antibodies market
Evaluation and identification of monoclonal antibodies based on the sources from
which they are derived and on the targets against which they act
Understanding the key regulations for registering, manufacturing and importing
monoclonal antibodies in India

2. Evaluating the patent details of all globally marketed monoclonal antibodies in India, US and
Europe
Identifying the patentee name and patent numbers of all in-market monoclonal
antibodies in India, US and Europe
Identifying the monoclonal antibodies that are patent protected in India, US and
Europe and those that are not
Estimating the patent expiries of various monoclonal antibodies in India, US and
Europe
Comprehensive situation analysis of the Indian monoclonal antibodies market
Analyzing current and future sales of monoclonal antibodies in India
Identifying all globally launched monoclonal antibodies and understanding their
performance and launch status in India
Analyzing the global and Indian monoclonal antibodies market by Indication
Evaluation of the top selling monoclonal antibodies
Key biosimilar antibody development programmes in India and abroad
Table of Contents
1 Market Definitions & Methodology
2 Executive Summary
3 Therapeutic Antibodies Market in India
3.1 Industry Analysis
3.1.1 Strengths
3.1.2 Weaknesses
3.1.3 Opportunities
3.1.4 Threats
3.2 Technological & Regulatory Assessment
3.2.1 Technological Assessment
3.2.2 Regulatory Assessment

3. 3.3 Patent Details of Various Monoclonal Antibodies: US, Europe & India
3.4 Market Analysis
3.4.1 Current & Future Sales Trends
3.4.2 Sales Breakup by Molecule
3.4.3 Sales by Indication
3.5 Evaluation of Top Monoclonal Antibodies
3.5.1.1 Avastin
3.5.1.2 Herceptin
3.5.1.3 Rituxan/Mabthera
3.5.1.4 Remicade
3.5.1.5 Humira
3.6 Biosimilar Case Studies
3.6.1 Reditux
3.6.2 Grafeel
3.7 Key Indian & Foreign Biosimilar Antibody Development Programmes
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-415-5099
IMARC Group North America
Email: america@imarcgroup.com
Phone: +1-631-791-1145

4. IMARC Group Europe, Middle East & Africa
Email:ema@imarcgroup.com
Phone: +44-702-409-7331
To know more please visit: http://www.imarcgroup.com/